RECOVER Closing Conference

Coordination of European COVID-19 Adaptive Platform Trials - TCB Jacques Demotes, Victoria C. Simensen

6-7 June 2023 Esplanade Hotel, Zagreb, Croatia






This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101003589.

Background

- RECOVER POR
- During the initial phases of the COVID-19 pandemic there were discussions on how Europe best could respond through multi-country clinical trials, including how to collaborate with the WHO facilitated Solidarity trial
- RECOVER and later EU RESPONSE received funding from the Horizon 2020 research programme to support COVID-19 clinical trials
- Both projects developed Adaptive Platform Trials with European REMAP-CAP and the establishment of EU-RESPONSE with Discovery (European Solidarity sister trial) and the EU Solid-Act trial
- The European Commission (RTD) requested a bridge between Adaptive Platform Trials in Europe to promote complementarity and avoid duplication and fragmentation
- An innovative "shared WP" between RECOVER and EU-RESPONSE was created
- This shared WP became responsible for coordination through three mechanisms: the Trial Coordination Board (TCB), the Joint Access and Advisory Mechanism (JAAM) and the platform trial Toolbox

Governance






Governance

- Request by the Commission to integrate two other EU-funded projects in the TCB;
 VACCELERATE and ECRAID-Prime (and ECRAID-Prime in JAAM)
- ECRAID-Prime to conduct early phase studies on new compounds- has expanded to syndromic research
- VACCELERATE includes three pan-European vaccine trials and an extended network
- A separate TCB Vx pillar was created for dialogue with vaccine investigators and stakeholders
- Joint TCB meetings are held when topics are of overarching relevance
- Plans for mandate and the benefits of dialogue to outlast Covid-19 pandemic
- The TCB secretariat at NIPH has become a beneficiary also in the MPX-RESPONSE project



Governance





- Objectives
- RECOVER and EU RESPONSE will deliver a comprehensive strategy for delivering adaptive platform trials
- The coordination mechanism led by ECRIN and NIPH, will ensure that the European COVID-19
 Adaptive Platform Trials are scalable and sustainable.
- The coordination mechanism will establish a dialogue with external stakeholders including the WHO, ECDC, European Medicines Agency (EMA), the HTAs (EUnetHTA), and the national competent authorities (CTFG), etc.
- The bridge between the clinical trial projects will guarantee complementarity, harmonization and synergies with other European and international projects, and will avoid fragmentation and redundancies.
- The momentum created by the Covid- 19 pandemic promoted transition in the research landscape by enforcing collaboration and harmonization through coordination





Methods – composition, structure of dialogue

	CORE TCB	69297 YOU
NIPH		John-Arne Røttingen (chair)
NIPH	Norwegian Institute of Public Health	Victoria C. Simensen
NIPH		Øyvind Melien
ECRIN	ecrin	Jacques Demotes (co-chair)
ECRIN		Paula Garcia, Sareema Javaid
EU Commission (obs)		Evelyn Depoortere, Stefanie Sowinski
EU Commission HERA	European Commission	Ulla Narhi, Corinna Hartung
RECOVER	and European C	Herman Goossens
EU RESPONSE		Yazdan Yazdanpanah
ECRAID-Prime	RESPONSE ecraid	Chris Butler
VACCELERATE	VACCELERATE	Oliver Cornely
MPX- RESPONSE		Yazdan Yazdanpanah



Methods – composition, structure of dialogue

TCB Tx PILLAR/ INVESTIGATORS				
EU FUNDED PARTNERS				
Discovery/SolidAct	🖐 Inserm		Dominique Costagliola	
SolidAct	i G	Oslo University Hospital	Marius Trøseid, Inge C. Olsen	
REMAP-CAP		My .	M.J.M. Bonten	
REMAP-CAP	ecraid	U S UMC Utrecht	Lennie Derde	
ECRAID-PRIME	Prime		Chris Butler	
Ε	UROPEAN AND G		RS	
Recovery	UNITED TO OXFORD	RECOVERY Randomised Evaluation of COVID-19 Therapy	Peter Horby	
Principle	University of Southampton	PARION Randomised trial of INterventions against COVID-19 In older peopLE	Chris Butler	
PANORAMIC		PANORAMIC Pletform Adaptive trial of NOvel antikrikalis for ack/y treatMent of COVID-19 in the Community	Paul Little	
AMMURAVID→MANTICO-2	di VERONA		Evelina Tacconelli	
ACTIV-3, TICO→STRIVE		STRIVE ACTIV INSIGHTO18	Jens Lundgren	
ANTICOV (DnDI)	ANTIC		Nathalie Strub-Wourgaft	



Methods – composition, structure of dialogue

	ТСР				
TCB Vx PILLAR/INVESTIGATORS					
	EU (FUNDED) PARTNERS				
EU-COVAT-1_AGED		ACCELERATE	Oliver Cornely		
EU-COVAT-2 BOOSTAVAC	T-2 BOOSTAVAC		Patrick Mallon		
EU-COVPT-1 COVACC	U-COVPT-1 COVACC		Patricia Bruijning-Verhagen		
	EUOP	EAN and GLOBAL	PARTNERS		
COMCOV, COMCOV-2			Mahesi Ramasay		
COMCOV-3	Comparing COVID-19 Vaccine Schedule Combinations	CoV-B			
COV-BOOST		ital	Saul Faust		
COVERALL			UKE Heiner Bucher		
MVA-SARS2-ST	Centre Hospitalier Viversitair Saint-Etenne		Marylyn de Addo		
COVIMMUNAGE		Care Ca	Elisabeth Botelho-Nevers		
CAR-CF	University of C	-	Silke van Koningsbruggen-Rietschel		
Recovac			Jan-Stephan Sanders		
MonkeyVax	AS PU	SISTANCE O HÔPITAUX	Liem binh Luong		



Methods – Composition, structure of dialogue

EXTENDED TCB					
POLICYMAKERS					
WHO HQ (Science Division)	World Health Organization	<i>ttt</i>	Vasee Morthy		
ECDC		ecoc	Howard Needham		
CEPI	CEPI		Bola Jones/Jakob Cramer/Christof Vinnemeier		
Therapeutics Accelerator (Wellcome/Gates)	erapeutics Accelerator (Wellcome/Gates)		Nick Cammack		
REGULATORS / ETHICS REPRESENTATIVES					
EUnetHTA			Claudia Wild		
EMA	EUROPEAN MEDICINES AGENCY	eunethta	Marco Cavaleri		
CTFG	Group		Ann Marie Janson Lang		
EUREC			Jacob Hølen/Elin Westerheim		
INDUSTRY					
EFPIA/VACCINES EUROPE	efpia		Magda Chlebus		
OTHER INITIATIVES					
Trial Forge	EU-PEARL		Shaun Treewek		
EU Pearl	EU PATIENT-CENTRIC CLINICAL TRIAL PLATFORMS		Cecile Spiertz		

Methods – dialogue, discussion and joint approaches



Design: how to create robust and harmonized CT protocols

(the role of APTs)

Conduct: regulatory and ethical approvals. New systems for multicounty approvals

Results: effectiveness and safety data and implications for use of care

Guidelines: do the trial design and results meet requirements of the guideline makers

Subpopulations: pregnant women, paediatric and immunocompromised repurposed and new drugs

Follow-up: existing platforms for the study of "long-covid" and secondary outcomes (PROMS) Outpatient trials: recruitment and infrastructure, combination treatments and syndromic research

Standardization: early data sharing. Collection and standardization of laboratory assessments

Results and outcome





COVID-19 harmonizing severity scales, EMA EU Pearl- EU RESPONSE dialogue, MPX RESPONSE-collaboration



Safety signals shared early, VHP+ and CTIS Experiences- Challenges in and outside of an emergency context



Remdesivir metaanlysis inspiration Impact of antigen status when using immunmodulatory drugs



The need for outpatient trials- funding, resourses, infrastructure

Results and outcomes



- Dissemination of ideas, results and experiences
 - accelerated research response to/in the crisis
- Inform and promote synergetic initiatives in Europe (GloPiD-R, EU-Pearl, TrialForge, WHO Science Division, WHO working group on community engagement, EMA stakeholder working group); how can these initiatives be exploited by trial networks
 - joint statements on the GloPiD-R roadmap and the WHA resolution on clinical trials
- Established a continuous communication channel between the trial networks and the Commission (incl. RTD, SANTE, HERA)
 - better exploitation of systems
- The WHO wants to explore the feasibility of more global collaboration, can similar coordination efforts be of interest in other regions and for other diseases?

Conclusions





- Coordination as a tool and a goal
- Coordination may be the key to success for the European clinical trials (notion of evidence is a global public good) -
- What is research success: needs-based, robust, effective and efficient, promotes sustainable exploitation of resources (harmonization), transferable and equitable in access and availability
- Keys to coordination are evidence, stakeholders, trust trust is built upon reliability, legitimacy, confidence
- The TCB is not us, it is all of you the core component of the TCB meetings is the opportunity for exchange and discussions

Impact

- The TCB has been a relevant and trusted forum during the Covid-19 pandemic
- Endorsed by investigators and stakeholders in the European research space
- Succeeded in lifting the notion that the research community is stronger together
- Inspired collaboration and new networks
- Can be further exploited as an instrument for communication and dialogue by the European Commission and HERA
- Could play a role in involving additional research networks and countries (e.g Eastern Europe) during crisis
- Facillitate for private-public partnerships




Lessons learned and further recommendations

- Coordination is useful in a time of crisis (and in interpandemic times)
- Coordination may be most constructive when prospective
- Coordination effects are linked to funding and authority need organized funding mechanisms to ensure timely response
- Coordination is dependent on the willingness to be coordinated, "steering vs nudging"
- Successful coordination should be maintained and sustained
 Further outlook: new funding, additional partners, expanded scope
- HORIZON-HLTH-2023-DISEASE-03-05: Pandemic preparedness and response: Sustaining established coordination mechanisms for European adaptive platform trials and/or for cohort networks
- Coordinator: NIPH, Partners: Ecrin, Ecraid, U Verona, Penta, Inserm, U Cologne
- Link to other preparedness initiatives





CoMeCT- Coordination Mechanism for Cohorts and Trials





Deliverables

N°	Deliverable	Lead	Status
9.1	1- Reports on the coordinated development and operational management of the European COVID-19 Adaptive Platform Trial	ECRIN	Approved
9.2	1-Report on the strategic vision and deployment of the European COVID-19 Adaptive Platform Trials	NIPH	Approved
9.3	Strategic plan for partnership with stakeholders, also including other relevant initiatives and clinical trials beyond the EU	NIPH	Approved
9.4	2-Reports on the coordinated development and operational management of the European COVID-19 Adaptive Platform Trial	ECRIN	Approved
9.5	2-Report on the strategic vision and deployment of the European COVID-19 Adaptive Platform Trials	NIPH	Approved
9.6	Report on tools, methodologies and sustainability model for Adaptive Platform Trial design and management, including blueprint for the creation and management of Adaptive Platform Trials in other disease areas beyond COVID-19	ECRIN	Approved

N°	Milestone	Lead	Status
14	Composition and terms of references of the TCB	NIPH	Acheived
15	Composition and terms of references of the JAAM	ECRIN	Acheived
16	Meetings of the platform development strategy board	NIPH	Acheived
17	OCToPUs webpage activated	ECRIN	Acheived
18	Adaptive Platform Trial methodology workshop	ECRIN	Acheived

Q&A

